ImmuneBridge: Funding, Investors & Team (Oct 2026)
To treat cancer, ImmuneBridge is creating allogeneic immunotherapies. Our basic technique promotes the development of immune stem cells obtained from cord blood and creates a fresh, adaptable, reliable, and plentiful cellular source for immunotherapies. For haematological malignancies, we are currently researching natural killer cell products. Next, we will attack solid tumours using the special benefits of our cellular source. The platform From cord blood, ImmuneBridge is developing a platform for scalable allogeneic immune cell therapy. Our innovative technique, which uses an unique tiny chemical, increases cord blood HSPCs by over 100,000 times while preserving their entire immunological potential and enables them to specialise into diverse cell types like NK cells, T cells, and macrophages.
ImmuneBridge has raised $17.9M across 2 funding rounds on record, the most recent a Seed of $7.7M announced in Mar 2026.
That round is in line with the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ImmuneBridge Company Profile and Key Stats
Latest funding round on record: Mar 2026.
ImmuneBridge Funding Rounds
ImmuneBridge raised $10.2M in an undisclosed round announced in Jan 2023.
3.2 years later, a Seed of $7.7M was announced in Mar 2026.
ImmuneBridge Founders and Leadership Team
Contact details for the ImmuneBridge team: 2 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →ImmuneBridge Funding Compared to Other Biotechnology Startups
ImmuneBridge's latest round of $7.7M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ImmuneBridge in Biotechnology and San Francisco
Companies Similar to ImmuneBridge
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
ImmuneBridge Funding FAQs
What does ImmuneBridge do?
To treat cancer, ImmuneBridge is creating allogeneic immunotherapies. Our basic technique promotes the development of immune stem cells obtained from cord blood and creates a fresh, adaptable, reliable, and plentiful cellular source for immunotherapies. For haematological malignancies, we are currently researching natural killer cell products. Next, we will attack solid tumours using the special benefits of our cellular source. The platform From cord blood, ImmuneBridge is developing a platform for scalable allogeneic immune cell therapy. Our innovative technique, which uses an unique tiny chemical, increases cord blood HSPCs by over 100,000 times while preserving their entire immunological potential and enables them to specialise into diverse cell types like NK cells, T cells, and macrophages.
How much funding has ImmuneBridge raised?
ImmuneBridge has raised $17.9M across 2 rounds on record. The most recent is a Seed of $7.7M announced in Mar 2026.
When did ImmuneBridge last raise funding?
ImmuneBridge's most recent funding round on record is a Seed of $7.7M, announced in Mar 2026.
Who founded ImmuneBridge?
FundedIQ lists Nina Horowitz (Founder) at ImmuneBridge.
Who is the CEO of ImmuneBridge?
Peretz Partensky is listed as CEO at ImmuneBridge.
Where is ImmuneBridge headquartered?
ImmuneBridge is based in San Francisco, California, United States.
How many employees does ImmuneBridge have?
ImmuneBridge is in the 11-50 employee band.
How does ImmuneBridge's funding compare to other Biotechnology startups?
ImmuneBridge's latest round of $7.7M is in line with the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's ImmuneBridge Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ImmuneBridge is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.